

**Shou-Ching Tang, MD, PhD, FACP, FRCPC**

Associate Dean for Translational Medicine

Frances Zupardo Endowed Professor in Cancer Research, LSU School of Medicine

Director of Phase I Clinical Trials

Associate Director, Clinical Research, LSU LCMC Health Cancer Center

Director of Phase I Clinical Trials

Hematology and Oncology

504-210-2666

tang2@lsuhsc.edu

1700 Tulane Ave

New Orleans, LA 70112

**Education**

MD, West China University of Medical, Medicine - 1982

Ph.D., University of Alberta, Molecular Biology, Division of Medical Oncology, 1988

Fellowship, Medical Oncology, Princess Margaret Hospital, Toronto, Canada - 1993 - 1995

**What I'm Working On**

Dr. Tang's translational research has focused on oncogenesis, drug resistance, molecular immunology and prognostic and predictive biomarkers. His laboratory discovered the anti-apoptotic protein BAG-1 as a prognostic factor in solid tumors; and developed novel BAG-1-targeted therapy. Dr. Tang currently has three active ACS/DOD grants for which he serves as co-investigator or collaborator.

**Biography**



Shou-Ching Tang, MD, PhD, FACP, FRCPC, is a world-renowned clinician scientist and cancer center administrator with a passion for cancer clinical and translational research and breast cancer prevention, diagnosis, and treatment. He is certified in medical oncology by the American Board of Internal Medicine and the Royal College of Physicians and Surgeons of Canada. He currently serves as associate dean of translational research and tenured professor at the LSU Health New Orleans School of Medicine, associate director for clinical research at the LSU LCMC Health Cancer Center, and director of the phase I clinical trials program.

As associate director for clinical research, Dr. Tang will be responsible for organizing research programs in clinical research that foster collaboration, innovation, and impact, and engaging members and facilitating careers in clinical cancer research. In addition, Dr. Tang will be working with junior clinical faculty as part of a mentoring program.

As the associate dean for translational research, Dr. Tang provides leadership and strategic direction on the clinical and translational research efforts across the LSU Health New.

Prior to joining the LSU LCMC Health Cancer Center, Dr. Tang was with the University of Mississippi Medical Center, where he served as the associate director for clinical and translational research at the Cancer and Research Institute, director of the phase I clinical trials and interdisciplinary experimental therapeutic program and chair of clinical leadership council for cancer service line. He has also held leadership positions at academic institutions and NCI-Designated Cancer Centers, including the Georgia Cancer Center; endowed chair in medical oncology at the Virginia Piper Cancer Institute; director of clinical research with the Allina Health System; professor and chief of hematology/oncology at the Denver Health Medical Center (University of Colorado); professor and director of breast program at the Mayo Clinic (Scottsdale, AZ); and associate cancer center director for clinical research at the University of Miami Sylvester Comprehensive Cancer Center. He currently serves on the Department of Defense (DOD) Clinical and Experimental Therapeutics 10 (CET-10) Peer Review Panel, SWOG Breast Cancer and Immunotherapy Committees. He is a senior member of the American Association for Clinical Oncology (ASCO) and American Association for Cancer Research (AACR) and Fellow of American College of Physician (ACP) and Royal College of Physicians and Surgeons of Canada (FRCPC).

Dr. Tang earned his doctorate with honors from West China University of Medical Sciences and a PhD degree in molecular biology from the University of Alberta in Edmonton, Alberta, Canada. He completed his medical oncology fellowship at the Princess Margaret Hospital (Toronto, Canada). After graduation, Dr. Tang served as the director of medical oncology and cancer research at the Newfoundland Cancer Treatment and Research Foundation and was a member of the specialty committee in medical oncology for the Royal College of Physicians and Surgeons of Canada, and the Canadian Association of Medical Oncologists (CAMO). Dr.

Tang founded the Asia International Breast Cancer Summit (AIBCS) and has chaired its annual meetings in Asia since its conception in 2007. He was the Founding President of the Atlantic Canada Oncology Group (ACOG) and the US Chinese Anticancer Association (USCACA). Dr. Tang serves on the editorial boards of six peer-reviewed international journals.

Dr. Tang is a Frances Zupardo Endowed Professor in Cancer Research.

### Research Interests

- Breast cancer patient care
- Clinical trials and drug development
- Drug resistance
- Immunotherapy
- Targeted therapy
- Translational research for biomarker development

### Previous Research

Tang, SC., Wynn, C., Le, T. et al. Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis. *Cancer Metastasis Rev* 44, 18 (2025). <https://doi.org/10.1007/s10555-024-10231-5>

John Schaub and Shou-Ching Tang. Beyond Checkpoint Inhibitors: The New Generations of Immunotherapy *Clinical and Experimental Medicine*, accepted, Dec 2024

Li K, Wang R, Liu GW, Peng ZY, Wang JC, Xiao GD, Tang SC, Du N, Zhang J, Zhang J, Ren H, Sun X, Yang YP, Liu DP. Refining the optimal CAF cluster marker for predicting TME-dependent survival expectancy and treatment benefits in NSCLC patients. *Sci Rep.* 2024 Jul 21;14(1):16766. doi: 10.1038/s41598-024-55375-0. PMID: 39034310; PMCID: PMC11271481.

Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Pihapaul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. *Clin Ther.* 2024 Mar;46(3):228-238. doi: 10.1016/j.clinthera.2024.01.004. Epub 2024 Feb 28. PMID: 38423866.

[Enhancement of TKI Sensitivity in Lung Adenocarcinoma Through m6A-dependent Translational Repression of Wnt Signaling by circ-FBXW7](#)

**July 1, 2023**

*Mol Cancer*

doi: 10.1186/s12943-023-01811-0

[Association of Ferroptosis with Severity and Outcomes in Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy: A Case-control Study](#)

**June 26, 2023**

*Mol Neurobiol*

doi: 10.1007/s12035-023-03448-y

[Transparent Tissue in Solid State for Solvent-free and Antifade 3D Imaging](#)

**June 9, 2023**

*Nat Commun*

doi: 10.1038/s41467-023-39082-4

[Genome-phenome Wide Association Study of Broadly Defined Headache](#)

**May 24, 2023**

*Brain Commun*

doi: 10.1093/braincomms/fcad167

[Associations of Cerebral Small Vessel Disease on the Features of Hematoma and Hematoma Expansion in Intracerebral Hemorrhage](#)

**June 1, 2023**

*Cerebrovasc Dis*

doi: 10.1159/000531152

[View More](#)